Human Vδ2 T Cells and Their Versatility for Immunotherapeutic Approaches
Open Access
Abstract
Gamma/delta (γδ) T cells are innate-like immune effectors that are a critical component linking innate and adaptive immune responses. They are recognized for their contribution to tumor surveillance and fight against infectious diseases. γδ T cells are excellent candidates for cellular immunotherapy due to their unique properties to recognize and destroy tumors or infected cells. They do not depend on the recognition of a single antigen but rather a broad-spectrum of diverse ligands through expression of various cytotoxic receptors. In this manuscript, we review major characteristics of the most abundant circulating γδ subpopulation, Vδ2 T cells, their immunotherapeutic potential, recent advances in expansion protocols, their preclinical and clinical applications for several infectious diseases and malignancies, and how additional modulation could enhance their therapeutic potential.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (R01-AI125097, R21-AI157864)
This publication has 205 references indexed in Scilit:
- Interleukin-15 biology and its therapeutic implications in cancerTrends in Pharmacological Sciences, 2012
- Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumoursBritish Journal of Cancer, 2011
- The aminobisphosphonate pamidronate controls influenza pathogenesis by expanding a γδ T cell population in humanized miceJournal of Experimental Medicine, 2011
- HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+T lymphocytesProceedings of the National Academy of Sciences, 2011
- Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinomaCancer Immunology, Immunotherapy, 2011
- Impact of age, gender, and race on circulating γδ T cellsHuman Immunology, 2010
- A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous γδ T cells☆☆☆European Journal of Cardio-Thoracic Surgery, 2010
- The PRY/SPRY/B30.2 Domain of Butyrophilin 1A1 (BTN1A1) Binds to Xanthine OxidoreductaseJournal of Biological Chemistry, 2009
- Graft-versus-host diseaseThe Lancet, 2009
- Cross-presenting human γδ T cells induce robust CD8 + αβ T cell responsesProceedings of the National Academy of Sciences, 2009